Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction
Authors:
- J.J.M.L. HoffmannJHJ.J.M.L. Hoffmann
- F.J.W. Van ReyFRF.J.W. Van Rey
- J.J.R.M. BonnierJBJ.J.R.M. Bonnier
- 1 March 1985
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 37 (5) , 567-572
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarctionJACC, 1984
- Acylated Streptokinase – Plasminogen Complex in Patients with Acute Myocardial InfarctionThrombosis and Haemostasis, 1984
- Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.Circulation, 1983
- Systemic thrombolytic therapy of acute myocardial infarction?Circulation, 1983
- Fibrinolytic effects of intracoronary streptokinase administration in patients with acute myocardial infarction and coronary insufficiency.Circulation, 1983
- A Comparison of Acylated Streptokinase-Plasminogen Complex and Streptokinase in Healthy VolunteersThrombosis and Haemostasis, 1982
- On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921)Thrombosis Research, 1981
- Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapyNature, 1981